News headlines about Neurocrine Biosciences (NASDAQ:NBIX) have been trending positive recently, Alpha One Sentiment reports. The research group, a service of Accern, identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.27 on Alpha One’s scale. Alpha One also gave media headlines about the company an impact score of 78 out of 100, indicating that recent press coverage is likely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have effected AlphaOne’s analysis:
- Neurocrine Biosciences, Inc. (NBIX) Insider Sells 10000 Shares of Stock (campdesrecrues.com)
- Neurocrine Biosciences, Inc. (NBIX) noted a price change of 2.57 … – Stocks Gallery (stocksgallery.com)
- Neurocrine Biosciences (NBIX) and STMicroelectronics N.V. (STM … – Investing News Update (investingbizz.com)
- Most Active Stocks To Monitor;) Editas Medicine Inc (EDIT), Neurocrine Biosciences, Inc. (NBIX) – usstockjournal (usstockjournal.com)
- Progenics PharmaceuticalsPGNX) and Neurocrine Biosciences (NBIX) Swings Under News Buzzer- AT&T Inc. (T) – Investing News Update (investingbizz.com)
A number of analysts recently weighed in on NBIX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $62.00 target price on shares of Neurocrine Biosciences in a report on Friday, March 17th. Oppenheimer Holdings Inc. set a $60.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, February 14th. Cowen and Company reissued a “buy” rating on shares of Neurocrine Biosciences in a report on Wednesday, February 15th. Jefferies Group LLC reissued a “buy” rating and issued a $58.00 price target on shares of Neurocrine Biosciences in a report on Tuesday, April 4th. Finally, JPMorgan Chase & Co. set a $60.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, April 12th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and sixteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $67.69.
Neurocrine Biosciences (NBIX) traded down 1.85% during trading on Wednesday, hitting $44.64. 1,062,224 shares of the company traded hands. The stock’s market capitalization is $3.93 billion. Neurocrine Biosciences has a 52 week low of $37.35 and a 52 week high of $55.38. The company’s 50 day moving average is $50.96 and its 200-day moving average is $45.27.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $0.23. During the same period in the prior year, the company posted ($0.22) EPS. Analysts predict that Neurocrine Biosciences will post ($2.46) earnings per share for the current year.
In related news, Director Corinne H. Nevinny sold 5,000 shares of the business’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $53.98, for a total value of $269,900.00. Following the sale, the director now owns 34,603 shares in the company, valued at $1,867,869.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin Charles Gorman sold 19,596 shares of the business’s stock in a transaction on Wednesday, April 12th. The stock was sold at an average price of $50.42, for a total transaction of $988,030.32. Following the completion of the sale, the chief executive officer now owns 332,913 shares in the company, valued at approximately $16,785,473.46. The disclosure for this sale can be found here. Insiders sold 104,360 shares of company stock worth $5,501,889 in the last 90 days. 4.80% of the stock is currently owned by company insiders.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/neurocrine-biosciences-nbix-receives-daily-media-impact-score-of-0-27/1889994.html
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.